First patient dosed in FDA-approved phase III lenzilumab study for COVID-19

,

On May 6, 2020, Humanigen announced that the first COVID-19 patient had been dosed in its previously announced Phase III study.

Tags:

Source: Humanigen
Credit:

Visit News/History Source